Oxford Immunotec Board Oks $100 Mln Share Repurchase, Reaffirms Q4 Growth View

(RTTNews) - Oxford Immunotec Global PLC (OXFD) announced that its board has approved a share purchase program, which would involve the purchase of up to $100 million of the Company's outstanding ordinary shares over a five-year period.

The share purchase program, which is subject to shareholder approval, will be presented for shareholder approval on or before the company's annual general meeting of shareholders on Tuesday, June 18, 2019.

"Today's announcement reflects our continued confidence in our independent growth prospects, and reinforces our commitment to deliver value to our shareholders. We believe the potential to repurchase our shares around recent levels represents a highly compelling opportunity to deploy some of the proceeds from the divestiture of our U.S. laboratory services business late last year," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec.